Researchers identify promising new therapies for ependymoma
Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options.
Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid and Rituximab in patients with indolent non-hodgkin's lymphoma during the 51st American Society of Hematology's annual meeting in New Orleans, LA.